These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results Terminated 2014-004145-27 A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with ... 2017-01-03 due-trials
Reported results 2014-004201-33 A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with Chronic Hepatitis B Virus (HBV) Infection 2016-12-29 due-trials
Reported results 2014-004751-31 A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with ... 2016-12-15 due-trials
Reported results Terminated 2015-005499-46 A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination with Other Therapeutics in Patients with Chronic Hepatitis B Virus (HBV) Infection (MONARCH) 2016-11-30 due-trials
Not reported Terminated 2016-000917-59 An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as evidenced by changes in liver biopsy ... 2016-11-29 due-trials
Ongoing 2018-003385-14 A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency... not-yet-due
Other 2019-000068-86 A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD) not-yet-due
Ongoing 2021-000687-30 A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia not-yet-due
Ongoing 2021-000688-57 A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia Kettős vak, placebo kontrollált IIb. fázisú vizsgálat az ARO APO... not-yet-due
Ongoing 2021-003680-10 A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome not-yet-due
Ongoing 2022-001135-85 A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia 2. fázisú, nyílt, kiterjesztett vizsgálat az ARO-APOC3 hosszútávú biztons... not-yet-due